Kairos VC is a company.
Key people at Kairos VC.
Kairos VC was founded by Jim Demetriades (Managing Partner and Founder).
Kairos VC was founded by Jim Demetriades (Managing Partner and Founder).
Key people at Kairos VC.
Kairos Ventures is a venture capital firm founded in 2015, headquartered in Beverly Hills, California, that invests in scientific discoveries, patents, and businesses from top universities and scientists, primarily in biotechnology, healthcare, medical therapeutics, and pharmaceuticals.[1][2][5] Its mission centers on commercializing world-changing ideas into viable businesses, with a focus on healthcare and technology sectors, supporting entrepreneurs through operating expertise from its team of seasoned builders.[2][5] The firm has made 57 investments, mostly in the US, with deals typically in the $10-50 million range, a higher-than-average exit rate (25 percentage points above peers), and peak activity in 2017; its latest $58 million fund closed in 2022.[1] Kairos Ventures impacts the startup ecosystem by bridging academia and commercialization, particularly in life sciences, with 4 lead investments and follow-ons in high-potential biotech firms like Vivodyne.[1][2]
Kairos Ventures was established in 2015 in North America by James Demetriades, with a core team of about 3 key employees, including figures like Principal Josh Palmer (Physical Sciences Investments), Investment Associate Dr. Stephanie Kawecki (Life Sciences), and COO/CFO Todd Thomson.[1][5] The firm emerged from a group of entrepreneurs experienced in diverse businesses, aiming to nourish leading scientific breakthroughs into commercial successes.[2] Its evolution has centered on deep-tech healthcare, with investments ramping up post-founding—top exits in 2015, peak deal flow in 2017, and continued activity through 2019 and beyond, including a 2021 seed in Vivodyne and a 2022 fund raise.[1]
(Note: Kairos HQ, a separate NY-based company-building studio focused on consumer brands like Bilt and Rhino with pre-seed/seed investments, shares naming similarities but differs in focus and location.[3][4])
Kairos Ventures rides the wave of deep-tech biotech and life sciences innovation, capitalizing on advances in therapeutics, medical tech, and pharmaceuticals amid rising demand for university-commercialized breakthroughs.[1][2] Timing aligns with post-2020 biotech funding surges and AI-enhanced drug discovery, where academic IP transfer is critical; market forces like aging populations and personalized medicine favor its US-heavy portfolio (55 investments).[1] The firm influences the ecosystem by accelerating scientist-led startups, fostering exits, and bridging labs to markets—evident in its 2022 fund amid sustained healthcare VC momentum.[1][5]
Kairos Ventures is poised to expand its life sciences dominance with its 2022 fund, targeting more biotech unicorns amid trends like AI-drug integration and precision medicine.[1][2] Evolving regulatory support for therapeutics and global health investments will shape its path, potentially boosting exits beyond its current strong baseline. Its influence may grow by deepening university partnerships, solidifying its role as a key player in commercializing science that reshapes healthcare—echoing its founding promise to back world-changing ideas.[1][2]
